… nintedanib and pirfenidone for the treatment of idiopathic pulmonary fibrosis. For other
progressive fibrosing ILDs, the mainstay of drug therapy is immunosuppression. However, it is …

… single pathophysiological chain-of-events that could account for all the features that
characterize IPF, allowing us to envision new therapeutic approaches to improve patient outcomes. …

… therapeutic target for this disease. This review summarizes the current state of lung mucin
research related to pulmonary fibrosis … be considered as a new therapeutic approach for IPF. …

… novel therapeutic approaches, including combination therapies and, eventually, therapies
aimed at not only blocking fibrosis but also promoting ATII-driven alveolar regeneration. …

Idiopathic pulmonary fibrosis (IPF) is a fibrosing interstitial lung disease that is, by definition,
progressive. Progression of IPF is reflected by a decline in lung function, worsening of …

… This last trial tested a different therapeutic approach, consisting of myeloablation with total-…
Based on preclinical evidence and clinical similarities between idiopathic pulmonary fibrosis (…

Pulmonary hypertension (PH) developing secondarily in pulmonary fibrosis (PF) patients (PF-PH)
is a frequent co-morbidity. The high prevalence of PH in PF patients is very concerning …

… in the lungs and highlight potential targets for anti-fibrotic therapies. … mice studies have
highlighted the importance of IMs in pulmonary fibrosis in models of radiation-induced pulmonary …

… Research questions To compare the efficacy of nintedanib and pirfenidone in the treatment
of progressive pulmonary fibrosis; and to compare the efficacy of anti-fibrotic therapy (…

… in patients with idiopathic pulmonary fibrosis. Methods: Using a large US insurance database,
we identified 8,098 patients with idiopathic pulmonary fibrosis between October 1, 2014 …